Stemina’s innovative cell based assays arise from the strategic convergence of two groundbreaking technologies: stem cells and metabolomics. As a result, Stemina discovers and validates small molecules as biomarkers for high throughput drug screening and disease diagnostics in an all human system. Metabolomics enables the discovery of small molecules that can be used as candidate biomarkers of disease and pharmacological efficacy or toxicity. The human embryonic stem cell metabolome is a source of candidate biomarkers to predict, diagnose or measure the progress of disease or toxic response. Stemina provides compound screening and diagnostic development for pharmaceutical and biotechnology industries and academia under contract services or joint discovery agreements using our proprietary metabolomics platform. Contact Stemina today to learn how our services can build confidence in efficacy, safety and disease diagnostics.
The Wisconsin State Journal reported the formation of a third stem cell company in Madison, Wisconsin. Stemina Biomarker Discovery will bring together the stem cell expertise of Dr. Gabriela Cezar and the University of Wisconsin with Dr. Cezar’s metabolomics platform technology to conduct drug screening and drug development.
